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Background: HER2 plays a critical role in the pathogenesis of many cancers and is linked to poor prognosis or
cancer metastases. Monoclonal antibodies, such as Herceptin against HER2-overexpressing cancers, have showed
satisfactory clinical therapeutic effect. However, they have difficulty to surmount obstacles to enter cells or
blood–brain barrier.
Results: In this study, a cell-penetrating peptide Arg9 was linked to the C-terminus of anti-HER2 single chain
antibody (MIL5scFv). Flow cytometry, confocal microscopy and electron microscopy analysis all revealed that Arg9
peptide facilitated the penetration of MIL5scFv into HER2-negative cell line NIH3T3 and orientate in mitochondria.
More interestingly, Western blot assay showed the potential enhanced bioactivity of MIL5scFv-Arg9 in HER2+ cell
line SKOV3, indicating that Arg9 could help large molecules (e.g. antibody) to penetrate into cells and therefore
enhance its anti-neoplastic function.
Conclusions: Our work represented an attractive by preliminary strategy to enhance the therapeutic effect of
existing antibodies by entering cells easier, or more desirable, surmounting the physical barriers, especially in
hard-to-reach cancers such as brain metastases cases.
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HER2 is highly expressed in approximately 30% patients
with breast or ovarian cancer [1] and represents a poten-
tial target for antibody mediated biological therapy
against cancers. In clinical investigation, Monoclonal
antibody herceptin/trastuzumab has shown satisfactory
curative effect in tumour treatment if combined with
chemotherapty. However, the effective rate of trastuzu-
mab monotherapy is no more than 25%. [2] One of the
reasons is difficulty for high-molecular-weight antibody
to surmount the physical barriers to arrive at the destin-
ation. Consequently more effective strategies are needed
to increase the permeability of antibody drugs against
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reproduction in any medium, provided the orantibody such as single chain antibody (scFv) or antigen
binding fragment (Fab) is one of the choices based on
the report that phage-selected anti-HER2 human scFvs
improved antibody induced HER2-mediated endocytosis
and displayed strong inhibitory activity on the HER2-
overexpressing cancer cell lines, though it is still uncer-
tain whether they have anti-tumour activity in vivo. [3]
Currently, cell penetrating peptides (CPPs), including
TAT and Arginine rich sequences, [4-6] have been iden-
tified to have the capacity to help protein, peptide, PNA,
siRNA or DNA to get across the biological membranes
into cells.[7,8] For example, β-galactosidase (120 kDa) in
its active form can be delivered by TAT to various
organs of mice after intraperitoneal injection, such as
the lung, liver, spleen and even brain.[9] TAT can also fa-
cilitate a single-chain antibody against Bcl-2 to penetrate
the mast cell and induce the cell apoptosis. [10] In
addition, a synthetic nine-D-arginine oligomer was also
reported to efficiently penetrate cell membrane possibly
due to its unusual arginine-rich sequence. [11] TheThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of such a small carrying engine. Moreover, it has been
reported that Arg9-peptide facilitated the internalization
of an anti-CEA immunotoxin and potentiated its specific
cytotoxicity to target cells.[12] Therefore, Arg9 was pre-
dicted to be useful in the delivery of biological molecules
to break through the physiologic barriers and enhance
the function of cargo molecules.
In this study, we report a novel fusion protein of Arg9
peptide linked to the C-teminus of the scFv protein
derived from an anti-HER2 antibody MIL5 (Chinaese Pa-
tent Number: 101591396). This novel Arg9-based delivery
system was developed to facilitate MIL5scFv to overcome
physical barriers such as cell membranes. Similar to Her-
ceptin, MIL5 inhibits the intrinsic tyrosine kinase activity
and down regulates the downstream signalling molecules
such as phosphor-Akt (data not shown here). Our experi-
ments showed that this new delivery system could help
MIL5scFv overcome the hurdle of the NIH3T3 cell mem-
brane (HER2 negative), and retaining or even improving
the specificity of the cargo protein to identify HER2 over-
expressing tumour cell line SKOV3. This underlined the
highly interesting results of this novel Arg9 based delivery
system in terms of facilitating antibody to penetrate the
bio-membrane and in the potential design of antibody
based therapeutic process against intracellular factors or
reaching hard-to-reach targets, such as cerebroma.
Results
Expression plasmid construction and protein purification
To construct the expression plasmid of MIL5scFv fused
with Arg9 at C-terminus, an Arg9 peptide encoding DNA
was introduced by specific primers (Figure 1.A). The
MIL5scFv and MIL5scFv-Arg9 gene were amplified by
PCR method and identified by agarose gel electrophoresis
(Figure 1B). Then genes were subcloned to pET32a(+)
plasmid, respectively, to obtain the expression plasmids
pET32a(+)/MIL5scFv-Arg9 and pET32a(+)/MIL5scFv.
Proteins were induced by 0.1 mM IPTG, collected from
the sonic supernatant and purified by affinity chromatog-
raphy. The purified protein were electrophoresed in 12%
SDS-PAGE (Figure 1C) and further identified by western
blot assay (Figure 1D) as the sample proteins based on the
predicted molecular weight of 49 kDa.
MIL5scFv-Arg9 remained the binding capacity to
membrane antigen
To investigate the capacity to bind membrane HER2 on
SKOV3 cells, MIL5scFv and MIL5scFv-Arg9 were conju-
gated with FITC in our lab (F/P quotient = 4.0 and 2.7,
respectively). As shown in Figure 1E, MIL5scFv-Arg9-
FITC (Figure 1E-2, at dilutions of 1:2, 1:10 and 1:50) had
identical membrane antigen-binding activity compared
to MIL5scFv-FITC (Figure 1E-3, at dilutions of 1:2, 1:10and 1:50). Herceptin-FITC incubated sample was set as
positive control (Figure 1E-1, at a dilution of 1:5000).
The results suggested that the additional Arg9 peptide
did not affect the overall function of the MIL5scFv or its
HRE2 biding capacity.
Arg9 could help cargo protein (MIL5scFv) to penetrate
into NIH3T3 cells
To investigate the translocation ability of MIL5scFv-Arg9,
we add diluted MIL5scFv-Arg9-FITC or MIL5scFv-FITC
(1:5, 1:25 and 1:125) to NIH3T3 cells (membrane HER2
negative). Samples were analyzed by flow cytometry after
two hours’ treatment (Figure 2A~C), or collected in differ-
ent time points for confocal microscopy analysis
(Figure 2E). In contrast to MIL5scFv (Figure 2C), the
fused Arg9 did facilitate MIL5scFv to penetrate into
NIH3T3 cells. This is shown through the fluorescence in-
tensity of the signal shown in Figure 2B. Confocal micros-
copy analysis again confirmed the enhanced translocation
of MIL5scFv-Arg9. After being treated with MIL5scFv
and MIL5scFv-Arg9 respectively for 30 minutes, fluores-
cent signal could be seen only in MIL5scFv-Arg9 treated
sample, suggesting that Arg9 could promote large mol-
ecule such as MIL5scFv to penetrate bio-membrane.
However, when incubation of MIL5scFv prolonged to
5 hours faint fluorescent signal appeared, possibly owing
to the non-specific diffusion of MIL5scFv into the weak-
ening cell membranes.
Arg9 could help cargo protein (MIL5scFv) to translocate
in the mitochondria in NIH3T3 cells
In an attempt to identify the possible pathway of trans-
location and localization of these two proteins, MIL5scFv
and MIL5scFv-Arg9 were labelled with 5 nm colloidal
gold particles. NIH3T3 cells were incubated with colloidal
gold labelled scFvs and observed through transmission
electron microscope to analyze the distribution of col-
loidal gold particles. As shown in Figure 3, in MIL5scFv-
Arg9 treated cells, gold particles could be seen inside of
the cell membrane after only one hour’s incubation
(Figure 3B). Another hour later, MIL5scFv-Arg9 managed
to enter mitochondrial membrane, and finally localized
specifically in the mitochondrial matrix after five hours’
incubation. In the case of MIL5scFv treated cells, gold
particles seemed to be located mainly in cytoplasm
(Figure 3E~G) through out the whole process. This
showed clearly that Arg9 did facilitate the penetration of
cell membrane and mediate the cargo molecule’s trans-
location into mitochondria in NIH3T3 cells.
MIL5scFv-Arg9 had stronger inhibitory activity to the
expression of phospho-akt in SKOV3 cells
HER2 positive cell line SKOV3 was treated with
MIL5scFv-FITC or MIL5scFv-Arg9-FITC. Samples were
Figure 1 Expression and identification of fused proteins. A: Construction of recombinant expression plasmids. pET32a(+)/MIL5scFv and
pET32a(+)/MIL5scFv-Arg9. B: Gene amplification of scFvs by PCR. Lane 1: MIL5scFv; lane 2: MIL5scFv-Arg9; lane 3: DNA marker DL2000 plus. C:
SDS-PAGE analysis of purified proteins. Lane 1: MIL5scFv; lane 2: MIL5scFv-Arg9; Lane 3: Protein marker. D: Western blot analysis of purified
proteins. Lane 1: MIL5scFv; lane 2: MIL5scFv-Arg9. The predicted molecular weight of MIL5scFv-Arg9 was about 49 kDa, which was almost the
same with that of MIL5scFv. E: Flow cytometry analysis of antigen-binding capacity of purified proteins. Proteins were labelled with FITC in our
lab. The F/P quotient of MIL5scFv-FITC is 4.0, while MIL5scFv-Arg9-FITC is 2.7. The cells were treated with labelled proteins on ice for 30 minutes
and detected by flow cytometry, respectively. 1: Cells treated with herceptin-FITC as positive control; 2: Cells treated with MIL5scFv-FITC; 3: Cells
treated with MIL5scFv-Arg9-FITC. MIL5scFv-FITC and MIL5scFv-Arg9-FITC was diluted as indicated (1:2, 1:10 or 1:50). The binding activity was
evaluated with MFI value marked on the right top of each panel and the results showed that they could bind membrane antigen HER2 in a
dose-dependent manner. MFI: mean fluorescence intensity. Data are representative of two independent experiments.
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Figure 2 Flow cytometry analysis and confocal microscopy observation of MIL5scFv-Arg9 to penetrate NIH3T3 cells (HER2 negative).
Cells were incubated with diluted MIL5scFv-Arg9-FITC or MIL5scFv-FITC at 37°C for 2 h and then detected by flow cytometry. A: Cells treated with
herceptin-FITC as negative control; B: Cells treated with MIL5scFv-Arg9-FITC; C: Cells treated with MIL5scFv-FITC. The intensity of fluorescence
signal was evaluated with MFI value marked on the right top of each panel. According to the fluorescence intensity, Arg9 could help MIL5scFv
penetrate NIH3T3 cells. Data are representative of two independent experiments. D: Confocal microscopy observation of MIL5scFv-Arg9 to
penetrate NIH3T3 cells. Cells were incubated with PBS (Control) or herceptin-FITC as negative control, MIL5scFv-Arg9-FITC (1:10) or MIL5scFv-FITC
(1:10) at 37°C and collected consecutively in 0.5 h, 1 h, 2 h and 5 h. The distribution of fluorescence signal in the cells was observed under a laser
scanning confocal microscopy. Fluorescent signal could be detected after 0.5 hour in MIL5scFv-Arg9 treated samples, while in MIL5scFv treated
samples, weak signal could be seen after 5 hours. Each panel was merged with two photos: FITC conjugated protein (green) and nuclei (blue,
cells were stained with Hoechst 33258), which were not shown respectively here.
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focal microscopy (Figure 4A). After 0.5 hour, fluorescent
signal could be seen in MIL5scFv-Arg9 treated sample,
indicating that Arg9 could help penetrate SKOV3 cells.
Furthermore, weaker intracellular fluorescent signal in
MIL5scFv treated sample could be seen contrasting to
MIL5scFv-Arg9 after 5 hours.
Furthermore, SKOV3 cells were treated and collected
for western blot analysis. As shown in Figure 4B, both of
MIL5scFv and MIL5scFv-Arg9 treated samples inindicated concentrations remained detectable inhibitory
effect on the expression level of phospho-Akt in SKOV3
cells. According to the normalized value of phospho-Akt
based on Akt, MIL5scFv-Arg9 was seemed more effect-
ive than MIL5scFv. The ratio was about 0.03 in
MIL5scFv-Arg9 treated sample contrasting to 0.2 in
MIL5scFv treated sample at the concentration of 4 μg/
ml, indicating that Arg9 could possibly improve the bio-
functional activity of cargo protein (MIL5scFv) to block
the HER2 downstream signal transduction.
Figure 3 Transmission electron microscope observation of gold labelled MIL5scFv-Arg9 in NIH3T3 cells. Cells incubated with PBS (panel
A), 5 nm colloidal gold labelled with MIL5scFv-Arg9 at 1:40 dilution at 37°C for 1 h, 2 h or 5 h (panel B~D); 5 nm colloidal gold labelled with
MIL5scFv at 1:40 dilution at 37 °C also for 1 h, 2 h or 5 h (panel E~G), respectively. In one hour, gold particles were found outside or on the
membrane of MIL5scFv treated cells (E), while particles can be seen in the endochylema of MIL5scFv-Arg9 treated sample (B). After two hours,
gold particles could be found inside cells both in MIL5scFv-Arg9 and MIL5scFv treated samples (C and E), though in figure F they seemed to be
near mitochondria. After five hours, the subcellular localization of gold particles in two samples were obviously different, in which MIL5scFv could
be seem still in the cytoplasm (D), but MIL5scFv-Arg9 aggregated mainly inside of the mitochondria (G).
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In this study, a fused gene MIL5scFv-Arg9 was developed
through recombinant gene engineering (Figure 1A~B). To
obtain the recombinant proteins, we transfected the ex-
pression vectors pET-32a(+)/MIL5scFv-Arg9 and pET-32a
(+)/MIL5scFv into E.coli Rosetta, respectively, and purified
proteins were obtained by affinity chromatography from
sonic supernatant (Figure 1C~D). Then SKOV3 cells were
treated with corresponding purified proteins and then
analyzed their binding capacity by flow cytometry method(Figure 1E). Our data showed that short peptide Arg9 did
not affect the functional conformation of MIL5scFv, and
MIL5scFv-Arg9 kept the identical antigen binding cap-
acity as well as MIL5scFv. Which was consistent with the
report that the Arg9 linked to N-terminus of cargo mol-
ecule scFv-EGFP could maintain the binding activities to
HBsAg and had much better internalization effect. [13]
Arg9 has been reported to have the ability to penetrate
the cell membrane. Although the exact mechanism of
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Figure 4 Enhanced translocation and stronger activity of MIL5scFv-Arg9 to downregulate phospho-Akt in SKOV3 cells (HER2 positive).
A: Confocal microscopy observation of MIL5scFv or MIL5scFv-Arg9 to penetrate SKOV3 cells; Cells were incubated with PBS (Control),
MIL5scFv-Arg9-FITC (1:10) or MIL5scFv-FITC (1:10) at 37°C and collected consecutively in 0.5 h, 2 h and 5 h. The distribution of fluorescence signal
in the cells was observed under a laser scanning confocal microscopy. Fluorescent signal could be detected after 0.5 hour’ treatment with
MIL5scFv-Arg9 contrasting to MIL5scFv treated samples. Each panel was merged with two photos: FITC conjugated protein (green) and nuclei
(blue, cells were stained with Hoechst 33258), which were not shown here; B: Effect of MIL5scFv or MIL5scFv-Arg9 on the expression of
phospho-Akt. SKOV3 cells were treated with diluted MIL5scFv or MIL5scFv-Arg9 (4, 20 or 50 μg/ml, respectively) as indicated, and herceptin
treated cells were set as positive control; C: Densities of phosphor-Akt were normalized based on densities of Akt shown in Figure 4B,
suggesting satisfactory enhanced effect of Arg9 in inhibiting the expression level of phospho-Akt in SKOV3 cells. The data shown are calculated
from two independent experiments.
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study, flow cytometry, confocal microscopy as well as
transmission electron microscope analysis were performed
successfully to identify the intracellular distribution and
location of MIL5scFv-Arg9 in NIH3T3 cells. Our results
clearly showed that the fusion protein MIL5scFv-Arg9
could strikingly enhance the cell penetration in a time-
dependent manner in contrast to the seemingly weakdiffusion of MIL5scFv across the cell membrane after a
long treatment for many hours (Figure 2). This diffusion
could take place after the bio-membrane was badly wea-
kened by the hour’s long treatment of the MIL5scFv. On
the other, it has been reported that Arg6 and Arg8 linked
to carbonic anhydrase exhibited the maximum
internalization into the macrophage cells and accumula-
tion in the nucleus among the (Arg)n(n= 4-16) peptides.
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penetration and the cell localization might depend on the
techniques, the cell line used and the characteristic of
fused proteins. [16] Therefore, our data demonstrated that
Arg9 was an ideal carrier to facilitate MIL5scFv to translo-
cate into endochylema.
The roles of mitochondria in energy production and
programmed cell death make this organelle a prime tar-
get in the treatment of some disease states. [17] A sig-
nificant challenge to mitochondrial drug delivery is the
impervious structure of the hydrophobic inner mem-
brane. Our data from transmission electron microscope
analysis further indicated that MIL5scFv-Arg9 was
located mainly in the mitochondria of NIH3T3 cells
(Figure 3), while MIL5scFv was only found in endochy-
lema. This suggested that the Arg9 peptide was respon-
sible for the enhanced ability of cell penetration and the
specific mitochondrial localization of the fusion protein.
Theoretical and experimental studies have revealed the
importance of lipophilicity and positive charge in mole-
cules that accumulate in the mitochondria. A modified
formula of Arg8 (Cholesteryl-R8) has showed high intra-
cellular selectivity toward mitochondria owing to the
guanidinium groups of the arginine residue. [18] In
addition, some antioxidants based on penetrating pep-
tide were shown to be located in mitochondrial.[19,20]
Thus, Arg9, a molecule of lipophilic nature with strong
positive charge as confirmed by Bioinformatic analysis,
seemed to be an ideal carrier to facilitate large proteins
to enter mitochondria.
Previous studies have also showed that anti-HER2
scFvs selected from phage library enhanced the endo-
cytosis of antigen and showed no growth or signalling
impact on HER2-overexpressing cells.[21] However, con-
troversial discoveries declared that the anti-HER2 scFv
screened from phage library can inhibit the HER2 signal-
ling, especially the phosphorylation of Akt.[3] In this
study, MIL5scFv-Arg9 showed excellent capacity pene-
trating into SKOV3 cells by the observation of confocal
microscopy, and also was identified by western blot ana-
lysis to possess stronger effect on inhibiting the expres-
sion of phospho-Akt in contrast to MIL5scFv (Figure 4).
These indicated that Arg9 could possibly enhance the
bio-functional effect of cargo protein in vitro and
in vivo. The single chain antibody against HER2 could
hardly play a parallel role of the whole antibody; how-
ever, with the help of Arg9, the fusion protein might be
able to assert a satisfactory inhibitory effect of tumour
cell proliferation or survival through the HER2-Akt sig-
nalling pathway.
Conclusions
Our data demonstrated that Arg9 peptide retained and
even enhanced the function of cargo molecule (MIL5scFv)with regard to the antigen binding and downstream signal
transduction in SKOV3 cells. Arg9 could obviously en-
hance the penetration of MIL5scFv into NIH3T3 cells,
and make the way for the cargo molecules to be located
mainly in mitochondria. When fused to specific antibody
or other macromolecules, Arg9 shows the potential of an
interesting and useful carrier for mitochondrial delivery of
specific antibody. In addition, the in vitro cell penetrating
activity of Arg9 should be further exploited for the study
of diverse endocellular biological events. Although our
work indicates the hypothesis and possibility of using
Arg9 to deliver antibody therapeutics in hard-to-reach
cancers such as brain metastases cases in vivo, [22] further
studies should be conducted to investigate its mechanism




pET-32a(+) vector was from Promega (Madison, WI,
USA); IPTG was from Sigma(USA); Ni2+–nitrilotriacetic
acid sepharose was from Chinese academy of sciences
(China); FITC was from Sigma; herceptin was purchased
from Genentech (USA); anti-Akt and anti-phospho-Akt
(Ser 473) were from Cell Signaling technology (USA);
RGSHis HRP conjugate (HRP_anti-His, HRP conjugated
anti-His antibody) was purchased from QIAGEN (Ger-
many); horseradish peroxidase-conjugated secondary
antibody was from Zhongshan Goldenbridge (China);
MIL5scFv and MIL5scFv-Arg9 were prepared in our
laboratory.
Cell lines and culture conditions
Human ovarian cancer cell line SKOV3 (high expression
level of HER2), and immortalized cell line NIH3T3 were
obtained from ATCC. The cells were cultivated in
DMEM (high level of glucose) supplemented with 100u/
ml of penicillin, 100u/ml of streptomycin and 10% fetal
bovine serum (FBS). All the cells were incubated in a
humidified incubator (Thermo, America) at 37°C with
5% CO2.
Construction of expression plasmids
MIL5 was an anti-HER2 antibody prepared in our labora-
tory. The variable genes of heavy and light chains were
amplified with specific oligo-primers and PCR method.
MIL5scFv gene was then synthesized using a (SG4)3
linker between light and heavy sequences. After amplifica-
tion, products were electrophoresed in 1.2% agarose gels.
MIL5scFv and MIL5scFv-Arg9 genes, in which Arg9 pep-
tide was fused to the carboxyl-terminus of MIL5scFv as
described in Figure 1, were subcloned into BamHI-Hind
III-digested pET-32a(+) vector (Promega, Madison, WI,
USA) to construct the expression plasmids pET-32a
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sequences of expression plasmids were further confirmed
by DNA sequencing analysis.
The sequence of sense primer was 5′-CGCGGATCC-
GATATCGTGATGACCC-3′, containing a BamHIsite.
The sequence of antisense primer was 5′-CCCAAGCTTT-
TACCGTCTCCGCCTGCGTCTCCTGCGTCTGGAGCT-
CACGGTCACCAGGG-3′, introducing the Arg9 peptide
gene and a Hind III restriction site, or 5′-CCCAAGCTTT-
TACCGTCTCCGCCTGCGTCTCC-3′, only introducing a
Hind III restriction site.
Prokaryotic expression and purification of recombinant
proteins
E. coli Rosetta cells were transfected with expression
plasmids and cultivated in 2 ×YT medium supplemented
with ampicillin to a final concentration of 100 μg/ml at
37 °C to a OD600 value of 0.5–1.0, respectively, followed
by another 12 hours’ shaking at 27°C after adding
0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG).
Cells were collected by centrifugation, resuspended and
lysed by sonication at 4°C in binding buffer (20 mM PB
supplemented with 300 mM NaCl, pH 8.0). After centri-
fugation, supernatant was immediately loaded onto a Ni2
+–nitrilotriacetic acid sepharose affinity column (Chinese
academy of sciences, China). After being washed with 10
volumes of a binding buffer, the column was loaded with
diluted imidazole (10 mM, 30 mM, 50 mM, 200 mM,
and 500 mM) in 20 mM PB, pH 8.0. The fusion proteins
were collected and desalted using Millipore column
(MWCO, 10000). The concentrations of purified pro-
teins were calculated by ultraviolet spectrophotometer.
SDS-PAGE and western blot analysis
Purified proteins were mixed with loading buffer to per-
form SDS-PAGE using 12% gel and detected with coo-
massie staining solution. The other resolved proteins
were transferred from the gel onto a nitrocellulose mem-
brane. The membrane was blocked with 5% milk for 1 h
at room temperature and then incubated with
HRP_anti-His at a dilution of 1:5000 in 5% milk for an
hour’s incubation at room temperature. After being
washed three times with TBS-T, the membrane was
detected by ECL and autoradiography.
To verify the expression levels of phospho-Akt,
SKOV3 cells were seeded in six-well plates and grown
for attachment for 12 h. Then the cells were serum-
starved for another 12 h and then treated with herceptin,
MIL5scFv or MIL5scFv-Arg9 at different concentrations
for 24 h. Cells were washed once with cold PBS and
lysed in M2 buffer (1 mol/L Tris-cl, 25% NP-40, 5 mol/L
NaCl, 0.5 mol/L EDTA, 0.5 mol/L EGTA, 10 μg/ml
aprotinin, 1 mol/L DTT, 10 mol/L PNPP, 1 mol/L
Na3VO4) for 3 min on ice, and collected with cell scrape.Cells were then centrifuged at 12000 rpm for 15 min at
4°C. The supernatant was collected for Western blot
analysis. The nitrocellulose membranes were incubated
overnight at 4°C with anti-Akt or anti-phospho-Akt (Ser
473) monoclonal antibody (Cell Signaling technology,
USA) and then incubated with horseradish peroxidase-
conjugated secondary antibody (Zhongshan Golden-
bridge, China). Other detection did as described above.
The experiments were carried out two times.
Flow cytometry assay
SKOV3 cells were harvested through centrifugation and
washed once with cold PBS (pH7.4) containing 2% FBS.
Cells were incubated in FITC labelled MIL5scFv
(MIL5scFv-FITC) or MIL5scFv-Arg9 (MIL5scFv-Arg9-
FITC) at different concentrations (1:2, 1:5, 1:10 dilution)
or herceptin (1:5000) for 30 min at room temperature.
Cells were then washed twice and analyzed by a FACS-
can cytometer (Becton Dickinson, Mountain View, CA).
NIH3T3 cells were harvested, collected and incubated
with FITC labelled herceptin (herceptin-FITC, 1:5000),
MIL5scFv-FITC or MIL5scFv-Arg9-FITC at different
concentrations (1:5, 1:25, 1:125) for 2 h at 37°C. Samples
were then analyzed as described above for evaluating the
ability of Arg9 in helping cargo molecule penetrate cell
membranes. The experiments were carried out two
times.
Confocal microscopy observation
Cells were grown on Glass Bottom Dish (3x105cells/
well) in complete medium for 24 hours at 37°C, treated
with MIL5scFv-FITC or MIL5scFv-Arg9-FITC for 1 h,
2 h or 5 h and then fixed with 4% paraformaldehyde.
After permeabilization with 0.1% Triton in PBS contain-
ing 2% FBS, the cells were exposed to Hoechst 33258
and resuspended in 100 μl PBS. Samples were observed
and photographed by laser scanning confocal micro-
scope using the Zeiss LSM 410 confocal laser system
connected to a Zeiss Axiovert 135 M microscope with
40_/1.2 C-Apochromat water immersion lens (Zeiss,
Jena, Germany). Green fluorescence of FITC was excited
with argon laser (488 nm for excitation with 525 nm
pass barrier filter for radioactive wave). The similar
results were obtained in two times experiments.
Transmission electron microscopy observation
Colloidal gold (CG, 5 nm) conjugated MIL5scFv and
MIL5scFv-Arg9 were prepared with redox method.
NIH3T3 cells were incubated for 1 h, 2 h or 5 h at 37 °C
with 5 nm CG-conjugated particles in serum free
DMEM medium (1:40 dilution) and fixed with 3% glu-
taraldehyde at 4 °C for 2 h, followed by being fixed with
1% osmium tetroxide.After dehydration, embedding,
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http://www.biomedcentral.com/1756-0500/5/336section, and staining treatment, transmission electron
microscopy (Philips CM120) was used for observation.
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